Fever News and Research

RSS
Lundbeck announces availability of ONFI Tablets in the U.S.

Lundbeck announces availability of ONFI Tablets in the U.S.

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

Bird flu updates

Bird flu updates

Chinese man dies of bird flu

Chinese man dies of bird flu

Mosquito borne Murray Valley Encephalitis warnings for NSW and North Victoria

Mosquito borne Murray Valley Encephalitis warnings for NSW and North Victoria

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pioneer in infectious disease medicine shares his perspectives in new podcast series

Pioneer in infectious disease medicine shares his perspectives in new podcast series

BBC News Magazine examines antiviral drug research

BBC News Magazine examines antiviral drug research

Government, humanitarian agencies respond to flooding in Philippines, warn of disease threat

Government, humanitarian agencies respond to flooding in Philippines, warn of disease threat

Study assesses evidence of immunosuppression in sepsis

Study assesses evidence of immunosuppression in sepsis

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

Yissum introduces novel technology for manufacturing an anti-malaria drug in tobacco

Yissum introduces novel technology for manufacturing an anti-malaria drug in tobacco

Affordable artemisinin using tobacco plants

Affordable artemisinin using tobacco plants

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Lab results change in consistent ways during the course of Kawasaki disease

Lab results change in consistent ways during the course of Kawasaki disease

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Researchers discover how bloodstream malaria infection manipulates immune system

Researchers discover how bloodstream malaria infection manipulates immune system

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.